Insulin Regulation of Lipolysis and Lipolysis Proteins
NCT03866408
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Mayo Clinic
- Last updated on ClinicalTrials.gov
- January 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Minnesota · 1
- Mayo Clinic in Rochester · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.